Autolus Cuts 13% Workforce, Seeks $15M Savings and $120–135M 2026 Revenue
Autolus Therapeutics will cut headcount by about 13% while doubling manufacturing output for commercial and clinical trial patients in 2026. The company reiterated full-year 2026 AUCATZYL net revenue guidance of $120–$135 million (up from $74 million in 2025) and anticipates achieving positive gross margin next year.
1. Operational Efficiency Initiative
Autolus Therapeutics will reduce its global workforce by approximately 13%, impacting all business areas, as part of a broader plan to improve operational efficiency and cost structure. The company also plans to double manufacturing output for commercial and clinical trial patients in 2026 to support growing demand.
2. Financial Guidance and Margin Outlook
Autolus reaffirmed 2026 AUCATZYL net product revenue guidance of $120 million to $135 million, a significant increase from $74 million in 2025, and anticipates achieving a positive gross margin next year on the back of expanded production and streamlined operations.
3. Cost Savings and Restructuring Charges
The workforce reduction is expected to deliver approximately $15 million in annualized operating expense savings starting in 2027, with total restructuring charges of around $8 million, primarily for severance and related costs to be recognized in the first half of 2026.
4. Cash Runway and Pipeline Progress
Based on current operating plans and forecasted AUCATZYL revenues, the company projects its cash, cash equivalents, and marketable securities will fund operations into the fourth quarter of 2027, while pivotal Phase 2 and Phase 1 clinical trials in leukemia, lupus nephritis, and multiple sclerosis remain on track.